A randomized, double-blind, single-dose, 3-way, parallel-group, comparator-controlled study to evaluate the pharmacokinetic, safety, tolerability, and immunogenicity of BP02 (trastuzumab) compared to Herceptin (EU approved and US-licensed) in healthy adult male volunteers.
Latest Information Update: 20 May 2021
At a glance
- Drugs Trastuzumab (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Acronyms BP02-101
- Sponsors CURATEQ BIOLOGICS PRIVATE LIMITED
- 20 May 2021 New trial record